Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Nov;40(5):504-9.
doi: 10.1097/00007890-198511000-00007.

Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts

Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts

A J Demetris et al. Transplantation. 1985 Nov.

Abstract

Twenty failed human liver allograft specimens obtained at the time of retransplantation procedures were studied using a panel of monoclonal antibodies (T11, T4, T8, NK, B1, OKM1, OKM5, Ia, DR). A clinicopathologic analysis was used to distinguish between graft failures secondary to rejection (n = 10) and those due, at least in part, to other causes (n = 10). T lymphocytes constituted the major infiltrating cellular population in the liver in rejection cases, but significant numbers of B cells and monocytes/macrophages were present also. Following transplantation, but not before, the bile duct epithelium, as well as portal and central vein and hepatic artery endothelium expressed DR/Ia antigens. These structures are preferential targets of the rejection reaction. The selective destruction of bile ducts in livers undergoing rejection was manifested in these patients by striking elevations of serum gamma glutamyl transpeptidase (GGTP) activity, a marker of biliary epithelial damage. The induced expression of DR/Ia antigens on structures targeted for immune destruction may be an important event in the pathogenesis of liver allograft rejection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) T lymphocytes (T11+) in the portal tract from case 1. Note the cells beneath the portal vein (PV) endothelium (large arrowhead), surrounding bile ductules (arrow), and relative restriction of T11+ cells to the portal tracts (T11 IPEX, hematoxylin; ×125). (b) Higher power (500×) of the above specimen showing T cells adjacent to and infiltrating a small bile ductule sectioned longitudinally (out-lined by arrows). (c) T cell lymphocytes (T11+) in liver tissue from case 4 showing tight clustering of inflammatory cells surrounding a small bile ductule (arrow, 250×). (d) Liver tissue from case 2 stained for Ia antigen, showing positivity in larger septa1 bile duct (BD), endothelium of hepatic artery (HA, arrowhead) and small bile ductuler, (arrows), which are surrounded by inflammatory cells (125×). (e) B lymphocyte (B1+) in a portal tract from case 7 showing a nodule of B cells. Bile ductules could not be seen in this portal tract (315×). (f) OKMl+ cells in tissue from case 13 showing numerous positive cells in the portal tracts. This case was complicated by sepsis and bacterial cholangitis (125×).

Similar articles

Cited by

References

    1. Demetris AJ, Lasky S, Van Thiel DH, Starzl TE, Dekker A. Pathology of hepatic transplantation: a review of 62 adult allograft recipients immunosuppressed with a cylcosporine steroid regimen. Am J Pathol. 1985;118:151. - PMC - PubMed
    1. Porter KA. Pathology of liver transplantation. Transplant Rev. 1969;2:129. - PubMed
    1. McLean IW, Nakane PK. Periodate-lysine-paraformaldehyde fixative: a new fixative for immunoelectron microscopy. J Histochem Cytochem. 1974;22:1077. - PubMed
    1. Si L, Whiteside TL, Schade RR, Starzl TE, Van Thiel DH. Studies of lymphocyte subsets in liver tissue of patients with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and normal controls. J Clin Immunol. 1984;4:262. - PMC - PubMed
    1. Hayry P. Intragraft events in allograft destruction. Transplantation. 1984;38:1. - PubMed

Substances